Atsena Therapeutics present positive clinical data for XLRS gene therapy program
Promising early clinical trial results suggest that ATSN-201, an investigational gene therapy for X-linked retinoschisis (XLRS), could offer a potential new treatment approach for this rate inherited retinal condition.